Nystatin and Triamcinolone Acetonide Ointment Recall Due to cGMP Deviations
Teligent Pharma is recalling all unexpired batches of Nystatin and Triamcinolone Acetonide Ointment (15g, 30g, and 60g tubes) nationwide due to current Good Manufacturing Practice (cGMP) deviations related to discontinuation of the stability study program.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. The hazard is a manufacturing-practice deviation (discontinuation of stability studies) that creates theoretical risk but is not associated with documented patient harm. The precautionary nature and lack of reported adverse events place this in the Moderate category.
Plain-English summary
Teligent Pharma, Inc. is recalling Nystatin and Triamcinolone Acetonide Ointment, USP in three package sizes: 15-gram tubes (NDC 52565-042-15), 30-gram tubes (NDC 52565-042-30), and 60-gram tubes (NDC 52565-042-60). The recall affects approximately 217,184 tubes distributed nationwide in the USA and Puerto Rico.
The recall is being issued because the firm is discontinuing its stability study program, which constitutes a deviation from current Good Manufacturing Practice (cGMP) standards. All products within their expiration dates are included in the recall.
Patients taking this medication should consult their healthcare provider or pharmacist before stopping use. Consumers with affected product should contact their pharmacy or healthcare provider for guidance on obtaining replacement medication or alternative treatment options.
The recalled product
- Product
- Nystatin and Triamcinolone Acetonide Ointment, USP, packaged in a) 15 grams tubes, NDC 52565-042-15; b) 30 grams tubes, NDC 52565-042-30; c) 60 grams tubes, NDC 52565-042-60, Rx Only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310.
- Manufacturer
- Teligent Pharma, Inc.
- Category
- Drug — Topical Ointment
- Affected units
- 217,184
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batch: a) 15125
- Exp. 2/28/2022
- 15385
- Exp. 3/31/2022
- 15613
- Exp. 5/31/2022
- 16027
- Exp. 9/30/2022
- 16204
- Exp. 11/30/2022
- 16376
- Exp. 1/31/2023
- 16707
- Exp. 3/31/2023
- b) 15385
- 15752
- Exp. 6/30/2022
- 15346
- 16188
- 16567
Distribution
Part of a larger recall action
This product is one of 37 recalled by Teligent Pharma, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 37 products in this recall →Related recalls
Same manufacturer · Teligent Pharma, Inc.
See all →- ModerateDesonide Ointment Recalled Due to cGMP Deviations
FDA (Drugs) · 2022-03-30
- ModerateTriamcinolone Acetonide Cream USP 0.1% Recall — Stability Study Discontinuation
FDA (Drugs) · 2022-03-30
- ModerateTriamcinolone Acetonide Ointment Recalled Due to cGMP Deviations
FDA (Drugs) · 2022-03-30
- HighDiflorasone Diacetate Ointment recalled due to discontinued stability studies
FDA (Drugs) · 2022-03-30
- ModerateClobetasol Propionate Cream USP 0.05% Recall for cGMP Deviations
FDA (Drugs) · 2022-03-30
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Clindamycin Phosphate Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls MYXREDLIN Insulin Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09